BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37697718)

  • 1. Recommended calcium intake in adults and children with chronic kidney disease-a European consensus statement.
    Evenepoel P; Jørgensen HS; Bover J; Davenport A; Bacchetta J; Haarhaus M; Hansen D; Gracia-Iguacel C; Ketteler M; McAlister L; White E; Mazzaferro S; Vervloet M; Shroff R
    Nephrol Dial Transplant; 2024 Jan; 39(2):341-366. PubMed ID: 37697718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.
    Bacchetta J; Schmitt CP; Bakkaloglu SA; Cleghorn S; Leifheit-Nestler M; Prytula A; Ranchin B; Schön A; Stabouli S; Van de Walle J; Vidal E; Haffner D; Shroff R
    Pediatr Nephrol; 2023 Sep; 38(9):3163-3181. PubMed ID: 36786859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA.
    Bakkaloglu SA; Bacchetta J; Lalayiannis AD; Leifheit-Nestler M; Stabouli S; Haarhaus M; Reusz G; Groothoff J; Schmitt CP; Evenepoel P; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2021 Feb; 36(3):413-425. PubMed ID: 33245331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
    Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
    Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.
    Shroff R; Wan M; Nagler EV; Bakkaloglu S; Cozzolino M; Bacchetta J; Edefonti A; Stefanidis CJ; Vande Walle J; Ariceta G; Klaus G; Haffner D; Schmitt CP;
    Nephrol Dial Transplant; 2017 Jul; 32(7):1114-1127. PubMed ID: 28873971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis.
    Shroff R; Wan M; Nagler EV; Bakkaloglu S; Fischer DC; Bishop N; Cozzolino M; Bacchetta J; Edefonti A; Stefanidis CJ; Vande Walle J; Haffner D; Klaus G; Schmitt CP;
    Nephrol Dial Transplant; 2017 Jul; 32(7):1098-1113. PubMed ID: 28873969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic kidney disease - Mineral bone disorders: Physiopathology and guidelines].
    Lavainne F; Guillot P; Figueres L
    Rev Med Interne; 2022 Apr; 43(4):225-232. PubMed ID: 35227526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce.
    McAlister L; Pugh P; Greenbaum L; Haffner D; Rees L; Anderson C; Desloovere A; Nelms C; Oosterveld M; Paglialonga F; Polderman N; Qizalbash L; Renken-Terhaerdt J; Tuokkola J; Warady B; Walle JV; Shaw V; Shroff R
    Pediatr Nephrol; 2020 Mar; 35(3):501-518. PubMed ID: 31667620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The demise of calcium-based phosphate binders-is this appropriate for children?
    Rees L; Shroff R
    Pediatr Nephrol; 2015 Dec; 30(12):2061-71. PubMed ID: 25543193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
    Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.